Programs
Our programs are focused on expanding the radiopharmaceutical
field through our own discovery programs and in collaboration
with our partners. CPDC’s expertise lies in both the pre-clinical
development of new diagnostic probes and advancing important
radiopharmaceuticals to the clinic and market.
Our programs are focused on expanding the radiopharmaceutical
field through our own discovery programs and in collaboration
with our partners. CPDC’s expertise lies in both the pre-clinical
development of new diagnostic probes and advancing important
radiopharmaceuticals to the clinic and market.
CARI
to uncover radiopharmaceutical
innovations arising from academic
discoveries and early enterprises in
Canada to evaluate and support the
commercialization capabilities of new
radiopharmaceutical assets.
Through different funding avenues, CPDC has been running this program since 2020 and has
one to three active projects at a given time. Current projects include the development of an
amino acid-based PET imaging agent for various cancers with Dr. Robert Britton (Simon Fraser
University) and a PET imaging agent for targeting proteins overexpressed in several rare
diseases with Dr. Neil Vasdev (CAMH).
Through different funding avenues, CPDC has been running this program since 2020 and has
one to three active projects at a given time. Current projects include the development of an
amino acid-based PET imaging agent for various cancers with Dr. Robert Britton (Simon Fraser
University) and a PET imaging agent for targeting proteins overexpressed in several rare
diseases with Dr. Neil Vasdev (CAMH).
